IOVA
Iovance Biotherapeutics Inc
NASDAQ · Biotechnology
$2.53
+0.17 (+7.20%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 224.68M | 337.04M | 333.93M | 362.22M |
| Net Income | -509,667,123 | 23.64M | 18.09M | 27.70M |
| EPS | — | — | — | — |
| Profit Margin | -226.8% | 7.0% | 5.4% | 7.7% |
| Rev Growth | — | +17.4% | +6.9% | +2.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 702.0K | 109.76M | 100.41M | 133.92M |
| Total Equity | 501.46M | 546.43M | 592.21M | 571.74M |
| D/E Ratio | 0.00 | 0.20 | 0.17 | 0.23 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -524,910,692 | 42.24M | 40.52M | 39.62M |
| Free Cash Flow | — | 21.56M | 19.96M | 24.65M |